Literature DB >> 28138615

Chronic fibrous-degenerative pancreatitis with involvement of adjacent organs and their dysfunction: contemporary approaches to surgical treatment.

Volodymyr Ivanovych Pylypchuk1, Marco Vito Marino, Andriy Yavorskyy.   

Abstract

BACKGROUND: Presently, there is no single opinion concerning the method preferable for surgical treatment of chronic pancreatitis (CP) with dysfunction of adjacent organs.
METHODS: Surgical treatment was applied to 144 patients with CP. In 54 (37.5%) patients, CP was complicated by dysfunction of adjacent organs. Particularly these were biliary hypertension (BH) in 36 (25%) patients and chronic duodenal obstruction (CDO) in 8 (5.5%) patients. In 5 (3.5%) patients, BH was combined with CDO, and another 5 (3.5%) patients had a combination of BH, CDO and venous hypertension (VH) of the portomesenteric area. In 24 patients with BH, we applied intraoperative monitoring of biliary pressure (IOM BP) in the process of performing duodenum-preserving pancreas resections. Frey's procedure was applied in 26 (48.1%) cases, where CP was complicated by the development of CDO, BH or CDO + BH. To correct BH, Frey's procedure was supplemented by application of hepatico-entero anastomosis (HEA) in 10 patients, pancreas lingual was excised; internal biliopancreatic anastomosis was applied in two patients. Beger's procedure was used in 2 (3.7%) patients, in which CP was complicated by BH + CDO + VH. Pancreaticoduodenal resection (PDR) according to Whipple was used in 5 (9.2%) cases. Longitudinal pancreatic-enteric anastomosis (LPEA) supplemented by HEA due to BH was applied to 8 (14.8%) patients.
RESULTS: The results of chronic treatment were traced in 23 (42.5%) patients throughout the period of 6 to 36 months. Life quality indicators appeared to be the best among the patients who underwent resection surgeries on the pancreas.
CONCLUSIONS: The method selected to treat surgically the patients with CP that involves adjacent organs and causes their dysfunction is duodenum-preserving resection surgeries on pancreas head, which in some cases should be supplemented by application of biliodigestive anastomosis or biliopancreatic diversion in the area of pancreas resection to eliminate the BH.

Entities:  

Keywords:  Chronic pancreatitis (CP); biliary hypertension (BH); duodenal obstruction; duodenum-preserving resections; venous hypertension (VH)

Year:  2016        PMID: 28138615      PMCID: PMC5244734          DOI: 10.21037/tgh.2016.05.10

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  5 in total

1.  [Duodenum preserving resection of the head of the pancreas: a standard procedure in chronic pancreatitis].

Authors:  M W Büchler; H U Baer; C Seiler; P U Reber; C Sadowski; H Friess
Journal:  Chirurg       Date:  1997-04       Impact factor: 0.955

2.  Chronic pancreatitis complicated by cavernous transformation of the portal vein: contraindication to surgery?

Authors:  Maximilian Bockhorn; Florian Gebauer; Dean Bogoevski; Ernesto Molmenti; Guellue Cataldegirmen; Yogesh K Vashist; Emre F Yekebas; Jakob R Izbicki; Oliver Mann
Journal:  Surgery       Date:  2010-08-04       Impact factor: 3.982

3.  Long-period pancreatic stenting for painful chronic calcified pancreatitis required higher medical costs and frequent hospitalizations compared with surgery.

Authors:  Morihisa Hirota; Tohru Asakura; Atsushi Kanno; Kazuhiro Kikuta; Kiyoshi Kume; Shin Hamada; Jun Unno; Hiromichi Ito; Hiroyuki Ariga; Atsushi Masamune; Kennichi Satoh; Fuyuhiko Motoi; Shinichi Egawa; Michiaki Unno; Tooru Shimosegawa
Journal:  Pancreas       Date:  2011-08       Impact factor: 3.327

4.  Significance of splenic vein thrombosis in chronic pancreatitis.

Authors:  Anil K Agarwal; K Raj Kumar; Shaleen Agarwal; Shivendra Singh
Journal:  Am J Surg       Date:  2008-06-30       Impact factor: 2.565

5.  Surgical management of chronic pancreatitis with portal hypertension--a 19-year experience.

Authors:  H Ramesh; George Jacob; A Venugopal; V Lekha; Manoj Jacob
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.